MacGirlley Rizqah, Mokgalaboni Kabelo
Department of Life and Consumer Sciences, College of Agriculture and Environmental Sciences, University of South Africa, Roodepoort, South Africa.
JMIR Res Protoc. 2023 Mar 14;12:e42193. doi: 10.2196/42193.
Type 2 diabetes mellitus is a chronic disease that contributes to an increasing global burden on the health system. It has a high chance of leading to macrovascular complications and cardiovascular disease. As an inflammatory condition, it would be essential to target inflammatory pathways when developing therapeutic drugs for type 2 diabetes mellitus.
We aimed to evaluate the effect of vitamin D on markers of inflammation and lipid profile among adult patients with diabetes.
A systematic review will seek studies published on Embase, Google Scholar, PubMed, Web of Science, and Science Direct. This planned systematic review and meta-analysis will be limited to randomized controlled trials; moreover, the search will include published studies regarding the effects of vitamin D on pro-inflammatory cytokines and lipid profiles. The review will include studies published from inception until December 30, 2022. The study identification and selection will be based on the eligibility criteria by 2 independent reviewers. Additionally, a meta-analysis will only be performed if more than 2 studies are available and explore the same outcomes, and this will be analyzed using RevMan (version 5.4.1). The quality and risk of bias will be assessed following the Cochrane risk of bias tool and Jadad checklist.
The process for searching literature review has already started, and this is conducted independently by 2 reviewers using a predefined eligibility and "participants, intervention, comparator, and outcome" criteria. This systematic review and meta-analysis will not require any direct involvement of patients and the public; thus, no ethical approval was required.
The findings obtained from the proposed study will be presented in scientific seminars, journal clubs, and conferences and published in peer-reviewed journals.
International Platform of Registered Systematic Review and Meta-analysis Protocols INPLASY202260022; https://inplasy.com/?s=INPLASY202260022.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/42193.
2型糖尿病是一种慢性病，给全球卫生系统带来日益沉重的负担。它极易引发大血管并发症和心血管疾病。作为一种炎症性疾病，在研发2型糖尿病治疗药物时，针对炎症途径至关重要。
我们旨在评估维生素D对成年糖尿病患者炎症标志物和血脂谱的影响。
将在Embase、谷歌学术、PubMed、科学网和科学直投上检索已发表的研究，进行系统评价。这项计划中的系统评价和荟萃分析将限于随机对照试验；此外，检索将包括关于维生素D对促炎细胞因子和血脂谱影响的已发表研究。该评价将纳入从开始到2022年12月30日发表的研究。研究的识别和选择将基于两名独立评审员的纳入标准。此外，只有在有两项以上研究且探讨相同结果时才进行荟萃分析，并使用RevMan（5.4.1版）进行分析。将按照Cochrane偏倚风险工具和Jadad清单评估质量和偏倚风险。
文献综述的检索过程已经开始，由两名评审员独立使用预定义的纳入标准和“参与者、干预措施、对照和结果”标准进行。这项系统评价和荟萃分析不需要患者和公众的任何直接参与；因此，无需伦理批准。
拟议研究获得的结果将在科学研讨会、期刊俱乐部和会议上展示，并发表在同行评审期刊上。
国际注册系统评价和荟萃分析方案平台INPLASY202260022；https://inplasy.com/?s=INPLASY202260022。
国际注册报告识别号（IRRID）：PRR1-10.2196/42193。
